All AbMole products are for research use only, cannot be used for human consumption.
Capmatinib (INCB28060) is a potent, orally available selective inhibitor of the c-MET receptor tyrosine kinase, a clinically validated cancer target. Capmatinib (INCB28060) exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. INCB28060 potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines. Capmatinib (INCB28060) potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro. Oral dosing of INCB28060 results in time- and dose-dependent inhibition of c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models, and INCB28060 is well tolerated at doses that achieve complete tumor inhibition.
Cancer Res. 2017 Jan 1;77(1):41-52.
Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer
Capmatinib (INCB28060) purchased from AbMole
Mol Cancer Ther. 2017 Nov;16(11):2399-2409.
Dual inhibition of Hedgehog and c-Met pathways for pancreatic cancer treatment
Capmatinib (INCB28060) purchased from AbMole
Nature. 2015 Jun 18;522(7556):349-53.
MET is required for the recruitment of anti-tumoural neutrophils.
Capmatinib (INCB28060) purchased from AbMole
 |
Source | Mol Cancer Ther (2017). Figure 4. INCB28060 (Abmole Bioscience. Houston, TX, USA) |
| Method | oral gavage | |
| Cell Lines | KPC and orthotopic transplant model mice | |
| Concentrations | 1 mg/kg | |
| Incubation Time | 7, 14 or 21 days | |
| Results | Importantly, the group with dual inhibitor treatment in addition to gemcitabine showed no metastases. This result suggests that the combination of c-Met and Hh inhibitors in addition to gemcitabine has significantly suppressed metastasis formation. |
 |
Source | Mol Cancer Ther (2017). Figure 3. INCB28060 (Abmole Bioscience. Houston, TX, USA) |
| Method | oral gavage | |
| Cell Lines | KPC and orthotopic transplant model mice | |
| Concentrations | 1 mg/kg | |
| Incubation Time | 7, 14 or 21 days | |
| Results | These results suggest that the resistance to the c-Met and Hh inhibitor is developed following a prolonged treatment of each individual inhibitor; however, the resistance may be overcome by combining both c-Met and Hh inhibitors. |
 |
Source | Mol Cancer Ther (2017). Figure 1. INCB28060 (Abmole Bioscience. Houston, TX, USA) |
| Method | oral gavage | |
| Cell Lines | KPC and orthotopic transplant model mice | |
| Concentrations | 1 mg/kg | |
| Incubation Time | 7, 14 or 21 days | |
| Results | The data suggest that combination of both inhibitors with gemcitabine shows a trend in shrinkage of primary tumor volume in both mouse models of PDA after one week of treatment regimen. |
. figure 3.jpg) |
Source | Can Res (2017). Figure 3.INC280 (Abmole Bioscience). |
| Method | ||
| Cell Lines | PDAC cells | |
| Concentrations | ||
| Incubation Time | ||
| Results | As expected, neither the Hh inhibitor nor the HGF/c-Met inhibitor affected the levels of total AnxA2 or P-Y23-AnxA2 in Panc10.05 cells in the singly cultured serum-reduced media (Fig. 3A and B; Supplementary Fig. S5E and S5F). It is likely the concentration of HGFand IGF-1 in serum-reduced media is lower than the effective thresholds. |
-2[1].jpg) |
Source | Nature (2015). Figure 3. PF-04217903 and INCB28060 (AbMole Bioscience) |
| Method | mice treatment in vivo and histological evaluation | |
| Cell Lines | B16F10 cells | |
| Concentrations | 40mg/kg PF-04217903 and 50mg/kg INCB28060 | |
| Incubation Time | 2 weeks | |
| Results | Systemic treatment of WT mice carrying B16F10 melanomas (which are dependent on MET14) with three different MET tyrosine-kinase inhibitors (PF-04217903, INCB28060 and JNJ-38877605), strongly reduced TAN recruitment . |
-1.jpg) |
Source | Nature (2015). Figure 2. PF-04217903 and INCB28060 (AbMole Bioscience) |
| Method | mice treatment in vivo and histological evaluation | |
| Cell Lines | B16F10 cells | |
| Concentrations | 40mg/kg PF-04217903 | |
| Incubation Time | 2 weeks | |
| Results | "Systemic administration of PF-04217903 decreased the weight and volume of B16F10 melanomas by 36% and 54%, respectively. Instead, MET knockdown in cancer cells only, led to 58% and 75% inhibition of tumour growth and volume.TAN inhibition by PF-04217903 was comparable in both Met-silenced and scrambled B16F10 melanomas." |
| Cell Experiment | |
|---|---|
| Cell lines | SUN-5 and SUN-1 cells |
| Preparation method | Optimal cell density used in the viability assay was predetermined for individual cell lines. To determine compound potency, cells were seeded into 96-well microplates at the appropriate density in media containing 1% to 2% FBS and supplemented with serial dilutions of INCB28060 in a final volume of 100 μL per well. After 72-hour incubation, 24 μL of CellTiter 96 AQueous One Solution (Promega) was added to each well, and the plates were incubated for 2 hours in a 37°C incubator. The optical density was measured in the linear range using a microplate reader at 490 nm with wavelength correction at 650 nm. IC50 values were calculated using the GraphPad Prism Software. |
| Concentrations | 0~333 nM |
| Incubation time | 3 days |
| Animal Experiment | |
|---|---|
| Animal models | B16F10 tumour-bearing mice |
| Formulation | 0.5% methylcellulose in saline |
| Dosages | 50mg/kg INCB28060 |
| Administration | via oral gavage every day once a day starting from day 2 after tumour injection and twice a day from day 11 until the end of the experiment(2 weeks) |
| Molecular Weight | 412.42 |
| Formula | C23H17FN6O |
| CAS Number | 1029712-80-8 |
| Solubility (25°C) | DMSO 15 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related c-Met Products |
|---|
| Zurletrectinib
Zurletrectinib (ICP-723) is a potent tyrosine kinase inhibitor. Zurletrectinib serves as an antineoplastic agent. Zurletrectinib can used for research of TRK-mediated related diseases. |
| ABN401
ABN401 is a highly potent and selective ATP-competitive c-MET inhibitor with an IC50 value of 10 nM. |
| (Z)-Semaxanib
(Z)-Semaxanib is a potent tyrosine kinase inhibitor. |
| MET kinase-IN-2
MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. |
| BMS-817378
BMS-817378 is a potent and selective inhibitor of MET with IC50 of 1.7 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
